Merck Manual

Please confirm that you are a health care professional

honeypot link

Disorders of Neuromuscular Transmission

(Neuromuscular Junction Disorders)

By

Michael Rubin

, MDCM, New York Presbyterian Hospital-Cornell Medical Center

Last full review/revision Apr 2022| Content last modified Apr 2022
Click here for Patient Education

Disorders of neuromuscular transmission affect the neuromuscular junction; they commonly cause fluctuating muscle weakness with no sensory deficits.

Disorders of neuromuscular transmission may involve

The most common disorder that affects neuromuscular transmission is myasthenia gravis.

Eaton-Lambert syndrome

Eaton-Lambert syndrome Neurologic paraneoplastic syndromes Neurologic paraneoplastic syndromes is due to impaired acetylcholine release from presynaptic nerve terminals. Repetitive nerve testing at rapid rates (20 to 50 hertz [Hz]) or a single supramaximal stimulation before and after 10 seconds of maximal isometric exercise shows an incremental response of up to 400%. Increases of > 100% are considered diagnostic of a presynaptic disorder of neuromuscular transmission, but an increment of ≥ 60% or greater is highly suggestive.

Botulism

Also due to impaired release of acetylcholine from presynaptic nerve terminals, botulism Botulism Botulism is poisoning that is due to Clostridium botulinum toxin and that affects the peripheral nerves. Botulism may occur without infection if toxin is ingested, injected, or inhaled... read more develops when toxin produced by Clostridium botulinum spores irreversibly binds to a specific receptor (synaptotagmin II) on the presynaptic terminal cholinergic nerve endings. The result is severe weakness, sometimes with respiratory compromise and difficulty swallowing. Other systemic symptoms may include mydriasis, dry mouth, constipation, urinary retention, and tachycardia due to unopposed sympathetic nervous system activity (anticholinergic syndrome). These systemic findings are absent in myasthenia gravis.

In botulism, electromyography (EMG) detects a mild decremental response to low-frequency (2- to 3-Hz) repetitive nerve stimulation but a pronounced incremental response after 10 seconds of exercise or with rapid (50-Hz) repetitive nerve stimulation.

Drugs or toxic chemicals

Aminoglycoside and polypeptide antibiotics decrease presynaptic acetylcholine release and sensitivity of the postsynaptic membrane to acetylcholine. At high serum levels, these antibiotics may increase neuromuscular block in patients with latent myasthenia gravis. Long-term penicillamine treatment may cause a reversible syndrome that clinically and electromyographically resembles myasthenia gravis Myasthenia Gravis Myasthenia gravis is characterized by episodic muscle weakness and easy fatigability caused by autoantibody- and cell-mediated destruction of acetylcholine receptors. It is more common among... read more . Excessive magnesium orally or IV (with blood levels approaching 8 to 9 mg/dL [4 to 4.5 mmol/L]) can also induce severe weakness resembling a myasthenic syndrome. Immune checkpoint inhibitors (eg, ipilimumab, nivolumab, pembrolizumab), a class of anticancer drugs, have immune-related adverse effects in < 1% of patients; however, these adverse effects (which include myasthenia gravis) continue to be reported.

Treatment consists of eliminating the drug or toxic chemical and providing necessary respiratory support and intensive nursing care. Atropine 0.4 to 0.6 mg orally 3 times a day decreases bronchial secretions in patients with cholinergic excess. Higher doses (eg, 2 to 4 mg IV every 5 minutes) may be necessary for organophosphate insecticide or nerve gas poisoning.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
quiz link

Test your knowledge

Take a Quiz! 
iOS ANDROID
iOS ANDROID
iOS ANDROID
TOP